NasdaqGS:BNTXBiotechs
Assessing BioNTech (NasdaqGS:BNTX) Valuation After Founders’ Planned Exit And Weakening COVID-19 Revenues
BioNTech (NasdaqGS:BNTX) is back in focus after its co founders, CEO Ugur Sahin and Chief Medical Officer Ozlem Tureci, said they will leave by the end of 2026 to start a new early stage mRNA company.
See our latest analysis for BioNTech.
The leadership news comes after a weak run for the stock, with a 7 day share price return of 10.16% and a 30 day share price return of 16.63%. The 1 year total shareholder return of 8.32% and 3 year total shareholder return of 29.66% point to fading momentum...